Tagged with Innovation,

Switzerland Laurent-Dominique Piveteau, CEO of Swiss medtech innovator Debiotech, discusses digital disruption, Swiss innovation, and future growth drivers. As well as being CEO of Debiotech, you also lecture courses at EPFL on “Economics of Innovation in the Biomedical Industry”. What are your thoughts on the incorporation of disruptive technologies in the…

Poland Jarek Oleszczuk, country president of AstraZeneca Poland, the leading R&D investor in Poland, discusses the exciting milestones that the company has achieved, including reimbursement of two breakthrough oncology therapies, as well as the company’s addition of 500 staff, representing now a 1,150-strong workforce. Furthermore, he touches on AstraZeneca’s key role…

Switzerland Jürgen Pohle provides both a fascinating and open account of the latest movements of Neovii; a company that possesses the ability to make decisions at the speed of a startup but also has a heritage dating back to the 1970s. After an outstanding career spanning 25 years with Big Pharma…

Poland Drago Vuina, corporate vice-president of Novo Nordisk Eastern Europe, highlights Poland as the most significant market in the region and the on-going commitment to make innovative treatment options available for patients. Furthermore, he discusses Novo Nordisk’s strong commitment to social responsibility in each country throughout the region and the need…

Switzerland Jeff Dufour, country manager Switzerland and BU lead Internal Medicine at Pfizer, discusses his first impressions of the country, his priorities for greater dialogue with Swiss healthcare insurers, and Switzerland’s potential as a ‘test market’ for the company. Can you give our international readers an outline of your background and…

Poland Jakub Szulc, director of life sciences at EY Poland, discusses the exciting opportunities that exist within the healthcare sector in the flourishing Polish economy and the overriding need to increase healthcare spending as the nation prepares for demographic changes in the future. Furthermore, he highlights the innovative services EY provides…

Austria Albin Egger, country representative of UCB Pharma Austria, discusses the strong performance of the Austrian affiliate within the global group, organizational restructuring, and the receptiveness of Austria to UCB’s innovative products. Globally, UCB registered nine percent growth for the first nine months of 2017. How would you describe the contribution…

Lithuania Marijus Valatka, general manager Lithuania, Latvia and Estonia at Novo Nordisk, explains the current challenges and areas for improvement in diabetes treatment in Lithuania and stresses the company’s commitment to not only bring medicines to the market but also enhance the quality of treatment fort diabetes and other serious chronic…

India Kanchana TK, director general of the Organisation of Pharmaceutical Producers of India (OPPI), the association which represents the interests of research-based pharmaceutical companies in India, discusses regulatory reform and how OPPI is helping to shape the Indian healthcare system. Please introduce yourself to our international readers and your journey to…

Canada Michael Rudnicki, chair of the Regenerative Medicine Alliance of Canada (RMAC) discusses the mandate of the newly established organization, the exciting potential of regenerative medicine, and Canada’s competitive edge in this cutting-edge field. Michael, could you share the mandate and mission of the newly established Regenerative Medicine Alliance of Canada…

Poland Denis Vujičić, managing director of MSD Poland, discusses his overriding mission to give Polish patients greater access to breakthrough therapies and highlights the affiliate’s extensive R&D capabilities that entail both domestic and global operations. Furthermore, he highlights the important steps that MSD is undertaking to strengthen its position as the…

Switzerland In an exclusive interview, Bruno Strigini, global CEO of Novartis Oncology, discusses the logic of the company’s separate oncology business unit, the significance of US FDA approval for the new CAR-T cell therapy, Kymriah, and the issues around pricing for this revolutionary treatment.   * Please note that this interview was…